Beta Drugs Limited

BETANotably above fair value

A 6-pillar fundamental profile. Each pillar scored 0–10.

5.6/10 composite
Prism for BETA.NS: composite 5.6 of 10, verdict Notably above fair valuePULSEQUALITYMOATSAFETYGROWTHVALUEn/a0.00.00.00.00.0

Pulse

— · Neutral

Pulse data unavailable; neutral placeholder

Pulse tracks recent momentum in price, analyst revisions, and news sentiment. Higher means stronger near-term tailwinds.

Quality

6.4 · Moderate

Piotroski 6/9, ROCE 19.1%

Quality captures profitability, return on capital, and earnings consistency. Higher means a better business.

Moat

7.0 · Moderate

Moderate moat

Moat estimates durable competitive advantages — brand, scale, switching costs. Higher means more defensible.

Safety

7.1 · Moderate

D/E 0.66, Int cov 9.5x

Safety looks at balance-sheet strength, leverage, and cash generation. Higher means lower financial risk.

Growth

7.5 · Strong

Rev CAGR 25.4%

Growth reflects revenue and earnings expansion over recent years. Higher means faster compounding.

Value

1.0 · Weak

MoS -29%, P/E 21.5

Value measures whether the stock is cheap relative to its intrinsic worth. Higher is cheaper.

Compare with another stock

Overlay BETA's prism against a peer.

Share this prism

Share on XWhatsApp

Get the full analysis

Interactive DCF, sensitivity, peer comparison, and AI summary for BETA.

Full analysis →

Model estimate. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.